INSIGHTS ON CONTRACT PHARMA MANUFACTURING

• How To Avoid GMP Manufacturing Pitfalls

  Common GMP pitfalls stem from poor scalability, late regulatory planning, weak tech transfer, unsuitable hosts, and inadequate quality systems, delaying biologics production timelines and budgets.

• Maintaining A State Of Control: EM And DES In Biopharma

  Partner with a proven team to streamline your facility validation and environmental monitoring programs with flexible, cGMP-compliant services and reliable on-site collection.

• Myths That Make Early CDMO Engagement Look Like A Risk

  Early CDMO engagement isn’t premature—it prevents CMC-driven delays, reduces comparability risk, and aligns AAV manufacturing decisions with long-term clinical and commercial success.

• Vendor To Visionary: Transforming AAV Manufacturing

  Early, collaborative CDMO partnerships optimize complex AAV development, enhancing manufacturability and reducing risks to shorten timelines more effectively than traditional transactional models.

• Beyond Particle Counting: Why Modern Biologics Need Particle Forensics

  High particle counts don’t always mean high risk. Identifying particle type and origin—not just quantity—avoids false alarms, protects timelines, and turns data into action.

• From Clinical To Commercial: Introducing Devices Earlier To Streamline The DDC Journey

  Uncover how early device strategy and integrated planning can streamline development, reduce risk, and accelerate your path to commercial success.

• Extreme Language: Ultra-High Potency

  Adapt to the next era of small-molecule therapies by recognizing ultra-high potency compounds and updating containment strategies, risk management, and infrastructure to meet their extraordinary demands.

• Targeted Modalities Set Elevated Standards For Precision

  Explore how targeted modalities like ADCs and TPDs are transforming precision medicine, unlocking new treatment opportunities, and overcoming development challenges to improve patient outcomes.

• Solubility Enhancement Strategies For Targeted Oral Therapies

  Explore how innovative technologies and strategic CDMO partnerships are unlocking the potential of next-generation targeted oral therapies, overcoming development challenges, and accelerating their path to patients.

• Cutting Through Complexity: An Integrated Model For Faster PFS Development

  Discover how integrated, end-to-end development for prefilled syringes can streamline timelines, enhance patient-centric delivery, and scale efficiently from early development to global launch.